Pfizer's vaccines head Kathrin Jansen to retire this year
Reuters
Published Apr 29, 2022 08:43PM ET
(Reuters) - Pfizer Inc (NYSE:PFE)'s vaccines head Kathrin Jansen, who led the development of the U.S. drugmaker's COVID-19 shot, has decided to retire later this year.
"Over the last two years, Kathrin's legendary resolve, stellar scientific intuition, and vaccine development expertise ushered in the first glimmer of hope for humanity in the middle of the pandemic," Chief Scientific Officer Mikael Dolsten said in a LinkedIn post announcing the retirement.
Pfizer developed the two-dose shot in collaboration with Germany's BioNTech. The vaccine became available in the United States under an emergency use authorization in late 2020 and is now the Western world's most widely used COVID-19 shot.
Jansen, who became the senior vice president of vaccine research and development in 2015, had been the chief scientific officer of the drugmaker's vaccine research and early development research unit.
She previously led vaccine research at vaccines and health care products maker Wyeth, which was acquired by Pfizer over a decade ago.
When contacted, Pfizer pointed to the LinkedIn post by Dolsten without providing additional comment.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.